Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acrivon TherapeuticsACRV +1.16%35 EV-to-EBITDA is 0.17 as of Aug. 13, 2026. GuruFocus rates ACRV with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 399 Biotechnology companies, Acrivon Therapeutics ranks better than 90.23% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Acrivon Therapeutics's enterprise value is $-13.37 Mil.
Acrivon Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-76.88 Mil. Therefore, Acrivon Therapeutics's EV-to-EBITDA for today is 0.17.
The historical rank and industry rank for Acrivon Therapeutics's EV-to-EBITDA or its related term are showing as below:
ACRV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.18
Current: 0.17
During the past 6 years, the highest EV-to-EBITDA of Acrivon Therapeutics was 0.18. The lowest was 0.00. And the median was 0.00.
ACRV's EV-to-EBITDA is ranked better than 90.23% of 399
companies
in the Biotechnology industry
Industry Median: 13.39
vs ACRV: 0.17
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Acrivon Therapeutics's PE Ratio (TTM) for today is calculated as:
Acrivon Therapeutics's share price for today is $1.74.
Acrivon Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Acrivon Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Acrivon Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrivon Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrivon Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Acrivon Therapeutics's EV-to-EBITDA falls into.
Acrivon Therapeutics's current Enterprise Value is $-13.37 Mil.
Acrivon Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-76.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acrivon Therapeutics (ACRV) has a EV-to-EBITDA of 0.17 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Acrivon Therapeutics. According to the industry distribution chart, Acrivon Therapeutics ranks #39 out of 399 companies in the Biotechnology industry, placing it in the top 9.8%.
Is Acrivon Therapeutics' EV-to-EBITDA too high?
Acrivon Therapeutics' current EV-to-EBITDA is 0.17. The Biotechnology industry median EV-to-EBITDA is 13.39. Acrivon Therapeutics' value of 0.17 is 98.7% below this industry median. Based on the distribution chart, Acrivon Therapeutics ranks #39 out of 399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Acrivon Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Acrivon Therapeutics' EV-to-EBITDA compare to SPRO and BSEM?
According to the Biotechnology industry distribution chart, Acrivon Therapeutics ranks #39 out of 399 companies for EV-to-EBITDA. This places Acrivon Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.39. Acrivon Therapeutics' value of 0.17 is 98.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.39, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acrivon Therapeutics's current EV-to-EBITDA of 0.17 is 98.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Acrivon Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acrivon Therapeutics's current EV-to-EBITDA is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrivon Therapeutics stock overvalued right now?
Acrivon Therapeutics (ACRV) has a current EV-to-EBITDA of 0.17. The current EV-to-EBITDA is 0.17 and 98.7% below the Biotechnology industry median of 13.39. Acrivon Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Acrivon Therapeutics (ACRV), the current EV-to-EBITDA is 0.17 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
35GF Score
Get the complete analysis for ACRV
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACRV has been successfully added to your 
